NCT02851589View on ClinicalTrials.gov

Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

November 30, 2018

Study Completion Date

November 30, 2019

Conditions
Acute Lymphocytic LeukemiaChronic Lymphocytic LeukemiaFollicular LymphomaMantle Cell LymphomaB-cell Prolymphocytic LeukemiaDiffuse Large Cell Lymphoma
Interventions
BIOLOGICAL

PCAR-019 (anti-CD19 CAR-T cells)

Trial Locations (1)

215123

RECRUITING

PersonGen BioTherapeutics (Suzhou) Co., Ltd., Suzhou

Sponsors
All Listed Sponsors
collaborator

Anhui Provincial Hospital

OTHER_GOV

lead

PersonGen BioTherapeutics (Suzhou) Co., Ltd.

INDUSTRY